Inventage Lab, Inc. (389470.KQ) Stock

389470.KQ logo

Inventage Lab, Inc.

389470.KQSouth Korea
Healthcare

Company profile

Inventage Lab reported revenue of 2.94 billion KRW for fiscal year 2025. Our analysis of its filings shows revenue growing from 658.15 million KRW in fiscal year 2023 to 2.94 billion KRW in fiscal year 2025, 111.3% a year on average. Inventage Lab reports about 81 full-time employees.

What stands out

  • Revenue rose 64.8% in fiscal year 2025, from 1.78 billion KRW in fiscal year 2024, after a rise of 170.9% the year before.
  • It reported a net loss in each of its last 5 fiscal years; the loss narrowed from 17.00 billion KRW in fiscal year 2024 to 8.46 billion KRW in fiscal year 2025.
  • Its net profit margin over the last four reported quarters was -127.0%, against a median of 4.6% for 6 listed companies of similar size in its industry.
  • It spent 19.45 billion KRW on research and development in fiscal year 2025, 6.6 times its revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Inventage Lab, Inc.

Inventage Lab, Inc., a platform technology company, develops medicines using microfluidics-based drug delivery systems. The company was founded in 2015 and is based in Seongnam-si, South Korea.

Largest shareholders

  • Ju-Hee Kim10.94 %10.94%
  • Dong-Hun Kim1.327 %1.33%
  • Choong-Ho Ryu0.9439 %0.94%
  • Byeong-Yul Jeong0.1675 %0.17%
  • Dong Seok Park0.1653 %0.17%

Share of the company, as of September 25, 2026

Leadership

  • Juhee Kim — Chief Executive Officer, 51
  • Donghoon Kim — VP & Director, 55

How much revenue does Inventage Lab make?

Inventage Lab reported 2.94 billion KRW in revenue for fiscal year 2025, up 64.8% from 1.78 billion KRW in fiscal year 2024.

What companies are similar to Inventage Lab?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include HLB Pharmaceutical Co., Ltd. (047920.KQ), JW Holdings Corporation (096760.KS), Korea United Pharm Inc. (033270.KS), Union Korea Pharm Co., Ltd. (080720.KQ).

How has Inventage Lab's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 1.86 billion KRW; FY2022, 3.72 billion KRW; FY2023, 658.15 million KRW; FY2024, 1.78 billion KRW; FY2025, 2.94 billion KRW.

Has Inventage Lab made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 9.27 billion KRW; FY2022, a loss of 10.60 billion KRW; FY2023, a loss of 26.99 billion KRW; FY2024, a loss of 17.00 billion KRW; FY2025, a loss of 8.46 billion KRW. It reported a net loss in each of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees81
FoundedMay 14, 2015
IPO DateNov 22, 2022
IPO StatusPublic
HeadquartersSeongnam-si, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
612, Woolim Lions Valley 3, Seongnam-si, 13403
Phone
82 31 608 0514
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Inventage Lab, Inc. (389470.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/389470.KQ

LinkedInLinkedInXXYouTubeYouTube